Publikationen

2014 | 20132012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000


2014

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Martinez-Saguer,I.; Cicardi,M.; Suffritti,C.; Rusicke,E.; Aygoren-Pursun,E.; Stoll,H.; Rossmanith,T.; Feussner,A.; Kalina,U.; Kreuz,W. Transfusion 2014. Vol 54:1552-1561

A review of immune tolerance induction with Haemate P in haemophilia A, Escuriola Ettingshausen C.; Kreuz,W. Haemophilia 2014. Vol. 20: 333-339

Inhibitors in patients with haemophilia A. Kreuz, W.; Ettingshausen, C.E. Thromb. Research 2014. In press

Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study. Kenet,G.; Bidlingmaier,C.; Bogdanova,N.; Ettingshausen,C.E.; Goldenberg,N.; Gutsche,S.; Halimeh,S.; Holzhauer,S.; Kurnik,K.; Limperger,V.; Junker,R.; Nowak-Gottl,U. Thromb. Res. 2014. Vol. 133: 544-549


2013

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Ettingshausen,C.E.; Kreuz,W. Haemophilia. 2013 Vol.19: 12-17

Factor VIII products and inhibitor development in severe hemophilia A, Gouw,S.C.; van der Bom,J.G.; Ljung,R.; Escuriola,C.; Cid,A.R.; Claeyssens-Donadel,S.; van,Geet C.; Kenet,G.; Makipernaa,A.; Molinari,A.C.; Muntean,W.; Kobelt,R.; Rivard,G.; Santagostino,E.; Thomas,A.; van den Berg,H.M., N.Engl. J. Med. 2013 Vol.368: 231-239

Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history. Aygoren-Pursun,E.; Martinez,Saguer,I; Kreuz,W.; Klingebiel,T.; Schwabe,D. Allergy 2013.Vol 68: 1034-1039

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A, Eckhardt,C.L.; van Velzen,A.S.; Peters,M.; Astermark,J.; Brons,P.P.; Castaman,G.; Cnossen,M.H.; Dors,N.; Escuriola-Ettingshausen,C.; Hamulyak,K.; Hart,D.P.; Hay,C.R.; Haya,S.; van Heerde,W.L.; Hermans,C.; Holmstrom,M.; Jimenez-Yuste,V.; Keenan,R.D.; Klamroth,R.; Laros-van Gorkom,B.A.; Leebeek,F.W.; Liesner,R.; Makipernaa,A.; Male,C.; Mauser-Bunschoten,E.; Mazzucconi,M.G.; McRae,S.; Meijer,K.; Mitchell,M.; Morfini,M.; Nijziel,M.; Oldenburg,J.; Peerlinck,K.; Petrini,P.; Platokouki,H.; Reitter-Pfoertner,S.E.; Santagostino,E.; Schinco,P.; Smiers,F.J.; Siegmund,B.; Tagliaferri,A.; Yee,T.T.; Kamphuisen,P.W.; van der Bom,J.G.; Fijnvandraat,K., Blood  2013, Vol. 122: 1954-1962

Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Cicardi,M.; Craig,T.J.; Martinez-Saguer,I.; Hebert,J.; Longhurst,H.J. Int. Arc. Allergy Immunol. 2013. Vol. 161: 3-9

Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience. Kurnik,K.; Auerswald,G.; Kreuz,W.Thromb. Res. 2013Risk of angioedema following invasive or surgical procedures in HAE type I and II - the natural history. Aygören-Pürsün E, Martinez Saguer I, Kreuz W, Klingebiel T, Schwabe D. Allergy. 2013 Vol.68: 1034-1039.


2012

Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Klingebiel T. Transfusion. 2012 Vol. 52: 100-107.

Management of bleeding disorders in children. Berntorp,E.; Halimeh,S.; Gringeri,A.; Mathias,M.; Escuriola,C.; Perez,R. Haemophilia 2012. Vol.18: 15-23

WAO Guideline for the Management of Hereditary Angioedema. Craig,T.; Aygoren-Pursun,E.; Bork,K.; Bowen,T.; Boysen,H.; Farkas,H.; Grumach,A.; Katelaris,C.H.; Lockey,R.; Longhurst,H.; Lumry,W.; Magerl,M.; Martinez-Saguer,I.; Ritchie,B.; Nast,A.; Pawankar,R.; Zuraw,B.; Maurer,M. World Allery Organ. J. 2012. Vol. 5: 182-199

Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies. Wahn,V.; Aberer,W.; Eberl,W.; Fasshauer,M.; Kuhne,T.; Kurnik,K.; Magerl,M.; Meyer-Olson,D.; Martinez-Saguer,I.; Spath,P.; Staubach-Renz,P.; Kreuz,W. Eur. J. Pediatr. 2012. Vol. 171: 1339-1348

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. Caballero,T.; Farkas,H.; Bouillet,L.; Bowen,T.; Gompel,A.; Fagerberg,C.; Bjokander,J.; Bork,K.; Bygum,A.; Cicardi,M.; de,Carolis C.; Frank,M.; Gooi,J.H.; Longhurst,H.; Martinez-Saguer,I.; Nielsen,E.W.; Obtulowitz,K.; Perricone,R.; Prior,N. J. Allergy. Clin. Immunol. 2012. Vol. 129: 308-320


2011

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH(R)) in 14 patients with severe haemophilia A, Bidlingmaier,C.; Kurnik,K.; Escuriola-Ettingshausen,C.; Jager,R.; Klamroth,R.; Male,C.; Marosi,A.; Nemes,L.; von,Stackelberg A.; Kreuz,W. Haemophilia 2011, Vol. 17: 837-840


2010

Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Martinez-Saguer,I.; Rusicke,E.; Aygoren-Pursun,E.; Heller,C.; Klingebiel,T.; Kreuz,W. Am. J. Obstet. Gynecol. 2010. Vol. 203: 131-137

Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Ettingshausen,C.E.; Kreuz,W. Haemophilia 2010. Vol. 16: 90-100

Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Martinez-Saguer,I.; Rusicke,E.; Aygoren-Pursun,E.; von,Hentig N.; Klingebiel,T.; Kreuz,W. Transfusion 2010. Vol. 50: 354-360

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Iorio,A.; Halimeh,S.; Holzhauer,S.; Goldenberg,N.; Marchesini,E.; Marcucci,M.; Young,G.; Bidlingmaier,C.; Brandao,L.R.; Ettingshausen,C.E.; Gringeri,A.; Kenet,G.; Knofler,R.; Kreuz,W.; Kurnik,K.; Manner,D.; Santagostino,E.; Mannucci,P.M.; Nowak-Gottl,U. J. Throm.Haemost. 2010. Vol.6: 1256-1265

Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, Heller C, Klingebiel T, Kreuz W. Am J Obstet Gynecol. 2010. Vol. 203: 131.e1-7.

HAE international home therapy consensus document. Longhurst,H.J.; Farkas,H.; Craig,T.; Aygoren-Pursun,E.; Bethune,C.; Bjorkander,J.; Bork,K.; Bouillet,L.; Boysen,H.; Bygum,A.; Caballero,T.; Cicardi,M.; Dempster,J.; Gompels,M.; Gooi,J.; Grigoriadou,S.; Huffer,U.; Kreuz,W.; Levi,M.M.; Long,J.; Martinez-Saguer,I.; Raguet,M.; Reshef,A.; Bowen,T.; Zuraw,B. Allergy Asthma. Clin Immunol. 2010. Vol.6: 22

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Aygoren-Pursun,E.; Martinez-Saguer,I.; Rusicke,E.; Klingebiel,T.; Kreuz,W. Allergy Asthma. Clin Immunol. 2010. Vol.6: 21

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Bowen,T.; Cicardi,M.; Farkas,H.; Bork,K.; Longhurst,H.J.; Zuraw,B.; Aygoeren-Pursun,E.; Craig,T.; Binkley,K.; Hebert,J.; Ritchie,B.; Bouillet,L.; Betschel,S.; Cogar,D.; Dean,J.; Devaraj,R.; Hamed,A.; Kamra,P.; Keith,P.K.; Lacuesta,G.; Leith,E.; Lyons,H.; Mace,S.; Mako,B.; Neurath,D.; Poon,M.C.; Rivard,G.E.; Schellenberg,R.; Rowan,D.; Rowe,A.; Stark,D.; Sur,S.; Tsai,E.; Warrington,R.; Waserman,S.; Ameratunga,R.; Bernstein,J.; Bjorkander,J.; Brosz,K.; Brosz,J.; Bygum,A.; Caballero,T.; Frank,M.; Fust,G.; Harmat,G.; Kanani,A.; Kreuz,W.; Levi,M.; Li,H.; Martinez-Saguer,I.; Moldovan,D.; Nagy,I.; Nielsen,E.W.; Nordenfelt,P.; Reshef,A.; Rusicke,E.; Smith-Foltz,S.; Spath,P.; Varga,L.; Xiang,Z.Y. Allergy Asthma. Clin Immunol. 2010. Vol.6: 24


2009

C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C, Klingebiel T. Transfusion. 2009. Vol.49: 1987-1995.

Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports, Streif,W.; Escuriola Ettingshausen C.; Linde,R.; Kropshofer,G.; Zimmerhackl,L.B.; Kreuz,W., Haemostaseologie 2009

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report, Valentino,L.A.; Carcao,M.; Mathew,P.; Leissinger,C.A.; Berntorp,E.; Blanchette,V.; Escuriola-Ettingshausen,C.; Ewenstein,B.; Ewing,N.; Gringeri,A.; Hoots,W.K.; Negrier,C., Haemophilia 2009, Vol.15: 959-965, Vol.29: 151-154


2008

Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Kessel C, Königs C, Linde R, Escuriola-Ettinghausen C, Stoll H, Klingebiel T, Dietrich U, Kreuz W. Mol Immunol. 2008. Vol. 46: 8-15.

Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Gosswein,T.; Kocot,A.; Emmert,G.; Kreuz,W.; Martinez-Saguer,I.; Aygoren-Pursun,E.; Rusicke,E.; Bork,K.; Oldenburg,J.; Muller,C.R. Cytogenet. Genoma.Res. 2008. Vol.121: 181-188

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Klarmann,D.; Martinez,Saguer,I; Funk,M.B.; Knoefler,R.; von,Hentig N.; Heller,C.; Kreuz,W. Haemophilia 2008. Vol. 14: 44-49

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Bowen,T.; Cicardi,M.; Bork,K.; Zuraw,B.; Frank,M.; Ritchie,B.; Farkas,H.; Varga,L.; Zingale,L.C.; Binkley,K.; Wagner,E.; Adomaitis,P.; Brosz,K.; Burnham,J.; Warrington,R.; Kalicinsky,C.; Mace,S.; McCusker,C.; Schellenberg,R.; Celeste,L. Hebert,J.; Valentine,K.; Poon,M.C.; Serushago,B.; Neurath,D.; Yang,W.; Lacuesta,G.; Issekutz,A.; Hamed,A.; Kamra,P.; Dean,J.; Kanani,A.; Stark,D.; Rivard,G.E.; Leith,E.; Tsai,E.; Waserman,S.; Keith,P.K.; Page,D.; Marchesin,S.;  Longhurst,H.J.; Kreuz,W.; Rusicke,E.; Martinez-Saguer,I.; Aygoren-Pursun,E.; Harmat,G.; Fust,G.; Li,H.; Bouillet,L.; Caballero,T.; Moldovan,D.; Spath,P.J.; Smith-Foltz,S.; Nagy,I.; Nielsen,E.W.; Bucher,C.; Nordenfelt,P. Ann. Allergy Asthma Immunol. 2008. Vol. 100: S30-S40


2007

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys. Kurnik,K.; Kreuz,W.; Horneff,S.; During,C.; Schobess,R.; Bidlingmaier,C.; Ettingshausen,C.E.; Krumpel,A.; Bogdanova,N.; Nowak-Gottl,U. Haematologica 2007. Vol. 92: 982-985

Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions. Aygoren-Pursun,E.; Martinez,Saguer,I; Rusicke,E.; Louwen,F.; Geka,F.; Ivaskevicius,V.; Oldenburg,J.; Klingebiel,T.; Kreuz,W. Am. J. Hematol. 2007. Vol. 82: 317-320


2006

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Ettingshausen,C.E.; Kreuz,W. Haemophilia 2006. Vol. 12: 102-106

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Berntorp,E.; Shapiro,A.; Astermark,J.; Blanchette,V.S.; Collins,P.W.; Dimichele,D.; Escuriola,C.; Hay,C.R.; Hoots,W.K.; Leissinger,C.A.; Negrier,C.; Oldenburg,J.; Peerlinck,K.; Reding,M.T.; Hart,C. Haemophilia 2006. Vol. 12: 1-7

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Bassus,S.; Wegert,W.; Krause,M.; Escuriola-Ettinghausen,C.; Siegemund,A.; Petros,S.; Scholz,T.; Scharrer,I.; Kreuz,W.; Engelmann,L.; Kirchmaier,C.M. Platelets 2006. Vol. 17: 378-384


2005

Role of von Willebrand factor in immune tolerance induction. Ettingshausen,C.E.; Kreuz,W. Blood Coagul. Fibrinolysis 2005. Vol. 16: S27-S31

Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. von,Auer Ch; Oldenburg,J.; von,Depka M.; Escuriola-Ettinghausen,C.; Kurnik,K.; Lenk,H.; Scharrer,I. Ann. N.Y. Acad. Sci. 2005. Vol. 1051: 498-505


2004

Long-term aspects of hemophilia B treatment: part I-role for prophylaxis. Ettingshausen,C.E.; Kreuz,W. Blood Coagul. Fibrinolysis 2004. Vol. 15: S11-S13

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. Bowen,T.; Cicardi,M.; Farkas,H.; Bork,K.; Kreuz,W.; Zingale,L.; Varga,L.; Martinez-Saguer,I.; Aygoren-Pursun,E.; Binkley,K.; Zuraw,B.; Davis,A.,III; Hebert,J.; Ritchie,B.; Burnham,J.; Castaldo,A.; Menendez,A.; Nagy,I.; Harmat,G.; Bucher,C.; Lacuesta,G.; Issekutz,A.; Warrington,R.; Yang,W.; Dean,J.; Kanani,A.; Stark,D.; McCusker,C.; Wagner,E.; Rivard,G.E.; Leith,E.; Tsai,E.; MacSween,M.; Lyanga,J.; Serushago,B.; Leznoff,A.; Waserman,S.; de,Serres J. J. Allergy Clin. Immunol. 2004. Vol. 114: 629-637

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. Agostoni,A.; Aygoren-Pursun,E.; Binkley,K.E.; Blanch,A.; Bork,K.; Bouillet,L.; Bucher,C.; Castaldo,A.J.; Cicardi,M.; Davis,A.E.; De,Carolis C.; Drouet,C.; Duponchel,C.; Farkas,H.; Fay,K.; Fekete,B.; Fischer,B.; Fontana,L.; Fust,G.; Giacomelli,R.; Groner,A.; Hack,C.E.; Harmat,G.; Jakenfelds,J. Juers,M.; Kalmar,L.; Kaposi,P.N.; Karadi,I.; Kitzinger,A.; Kollar,T.; Kreuz,W.; Lakatos,P.; Longhurst,H.J.; Lopez-Trascasa,M.; Martinez-Saguer,I.; Monnier,N.; Nagy,I.; Nemeth,E.; Nielsen,E.W.; Nuijens,J.H.; O'grady,C.; Pappalardo,E.; Penna,V. Juers,M.; Kalmar,L.; Kaposi,P.N.; Karadi,I.; Kitzinger,A.; Kollar,T.; Kreuz,W.; Lakatos,P.; Longhurst,H.J.; Lopez-Trascasa,M.; Martinez-Saguer,I.; Monnier,N.; Nagy,I.; Nemeth,E.; Nielsen,E.W.; Nuijens,J.H.; O'grady,C.; J. Allergy Clin. Immunol. 2004. Vol.114: 51-131


2003

Epidemiology of inhibitors and current treatment strategies. Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group. Haematologica. 2003 Jun;88(6):EREP04. Review.

Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Nowak-Gottl,U.; Escuriola,C.; Kurnik,K.; Schobess,R.; Horneff,S.; Kosch,A.; Kreuz,W.; Pollmann,H. Haemostaseologie 2003. Vol. 23: 36-40


2002

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Kreuz,W.; Ettingshausen,C.E.; Zyschka,A.; Oldenburg,J.; Saguer,I.M.; Ehrenforth,S.; Klingebiel,T. Semin. Thromb. Hemost. 2002. Vol. 28: 285-290

Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Ettingshausen,C.E.; Kurnik,K.; Schobess,R.; Kreuz,W.; Halimeh,S.; Pollman,H.; Nowak-Gottl,U. Blood 2002. Vol. 99: 1499-1500

Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Funk,M.B.; Schmidt,H.; Becker,S.; Escuriola,C.; Klarmann,D.; Klingebiel,T.; Kreuz,W. Haemophilia 2002. Vol. 8: 98-103


2001

Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Escuriola,Ettingshausen C.; Halimeh,S.; Kurnik,K.; Schobess,R.; Wermes,C.; Junker,R.; Kreuz,W.; Pollmann,H.; Nowak-Gottl,U. Thromb. Haemost 2001. Vol. 85: 218-220


2000

Is recombinant tissue plasminogen activator an option in the treatment of meningococcus-induced purpura? Veldman, A.; Ehrenberg,A.; Jager,G.; Ettingshausen,C.E.; Schneider,W.; Kreuz,W. Crit Care Med. 2000. Vol. 28: 598-600

Labor
...unser Gerinnungslabor
Anfahrt & Kontakt
...der Weg zu uns

News & Press

  • Tag der offenen Tür 2014

    "Tag der offenen Tür" im Hämophilie Zentrum Rhein Main (HZRM) war ein voller Erfolg. Etwa...

  • Medien

    Hier finden Sie die veröffentlichten Filmbeiträge und Zeitungsberichte über das Hämophilie -...

 

Publikationen

Hier finden Sie die Publikationen unserer Ärzte.